[2-(1H-inden-2-yl)ethyl]dimethylamine | 92039-36-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: [2-(1H-inden-2-yl)ethyl]dimethylamine
• 英文别名: 2-(1H-inden-2-yl)-N,N-dimethylethan-1-amine；2-<2-(N.N-Dimethylamino)-ethyl>-inden；2-(2-N.N-Dimethylaminoaethyl)inden；2-<2-Dimethylamino-aethyl>-inden；[2-(1H-inden-2-yl)-ethyl]-dimethyl-amine；2-(1H-inden-2-yl)-N,N-dimethylethanamine
• CAS: 92039-36-6
• 化学式: C₁₃H₁₇N
• 分子量: 187.285
• InChiKey: LQRAANQUDDMAOP-UHFFFAOYSA-N

物化性质

• 沸点：
  277.0±19.0 °C(Predicted)
• 密度：
  0.998±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  [2-(1H-inden-2-yl)ethyl]dimethylamine 、 2-溴丙腈 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 生成 [2-(1H-inden-2-yl)-ethyl]-dimethyl-amine
  参考文献：
  名称：

  新型茚H 1-抗组胺药治疗失眠症的选择性分析

  摘要：

  在寻找潜在改善的镇静催眠药的过程中，评估了H 1-抗组胺（-）- R-二甲基茚的一系列茚类似物的选择性。茚核心中6位取代基与丰富的电子侧链结合的变化导致鉴定出几种有效的H 1-抗组胺药，它们对CYP酶，M 1毒蕈碱受体和hERG通道具有理想的选择性。这些化合物是进一步ADME分析和体内评估的候选药物。

  DOI：

  10.1016/j.bmcl.2010.02.055
• 作为产物：
  描述：

  苄基丙二酸二乙酯 在 盐酸 、 sodium hydroxide 、 sodium tetrahydroborate 、 PPA 、 sodium hydride 作用下， 以 乙醇 、 溶剂黄146 、 甲苯 为溶剂， 反应 14.83h， 生成 [2-(1H-inden-2-yl)ethyl]dimethylamine
  参考文献：
  名称：

  Structure−Activity Relationships of Dimethindene Derivatives as New M₂-Selective Muscarinic Receptor Antagonists

  摘要：

  A series of 2,3-disubstituted indenes, which are analogues of the widely used histamine H, receptor antagonist dimethindene, have been synthesized and studied as muscarinic and histamine receptor antagonists. The affinities of these compounds for the five human muscarinic receptor subtypes (M-1-M-5) and for human histamine H, receptors were determined in radioligand binding studies using membranes from transfected Chinese hamster ovary (CHO) cells and [H-3]N-methylscopolamine ([H-3]NMS). The results demonstrate that the diisopropyl analogue 19 has a similar high affinity as (S)-dimethindene at M-2 receptors ((S)-dimethindene: pK(i) = 7.52; (-)-19: pK(i) = 7.37) with an improved selectivity pattern ((S)-dimethindene: M-2/M-1 = 6-fold, M-2/M-3 = 5-fold, M-2/M-4 = 10-fold, M-2/M-5 = 25-fold; (-)-19: M-2/M-1 = 36-fold, M-2/M-3 = 96-fold, M-2/M-4 = 42-fold, M-2/M-5 = 275-fold). In addition, compound (-)-19 showed 35-fold lower affinity at histamine H-1 receptors (pK(i) = 5.61) than (S)-dimethindene (pK(i) = 7.16). Another interesting compound is the fluoroethyl derivative 20 (pK(i)/M-2 = 7.49), which also exhibits a higher M-2 selectivity (M-2/M-1 = 19-fold; M-2/M-3 = 22-fold; M-2/M-4 = 13-fold; M-2/ M-5 = 62-fold) than (S)-dimethindene. Unfortunately, compound 20 also shows a high affinity for histamine H-1 receptors (pK(i) = 8.14). The compound with the highest affinity for M-2 receptors (pK(i) = 7.91), the dimethylaminomethylene analogue 31, displayed only a small preference for M-2 receptors. In conclusion, compound (-)-19 might be useful to test the hypothesis that blockade of muscarinic M-2 receptors in the brain is a viable mechanism by which to produce improved cognition. This second-generation dimethindene analogue might also be the starting point for the development Of M-2-selective muscarinic antagonists useful for quantifying M-2 receptors in the central nervous system with positron emission tomography imaging.

  DOI：

  10.1021/jm020895l

文献信息

• [EN] SLEEP INDUCING COMPOUNDS AND METHODS RELATING THERETO<br/>[FR] COMPOSES INDUCTEURS DE SOMMEIL ET METHODES ASSOCIEES
  申请人：NEUROCRINE BIOSCIENCES INC

  公开号：WO2005097093A1

  公开（公告）日：2005-10-20

  Compounds having the following structure: (I) including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, L1, L2 and n are as defined herein. Pharmaceutical compositions containing one or more compounds of structure (I), as well as methods relating to the use thereof, including methods for treating insomnia, inducing sleep or inducing sedation or hypnosis, are also disclosed.

  具有以下结构的化合物：(I) 包括立体异构体、前药和其药用可接受的盐，其中R1、R2a、R2b、R3、R4、R5a、R5b、L1、L2和n如本文所定义。包含一个或多个结构(I)的化合物的药物组合物，以及与其使用相关的方法，包括用于治疗失眠、诱导睡眠或诱导镇静或催眠的方法，也被披露。
• Sleep inducing compounds and methods relating thereto
  申请人：Moree J. Wilna (Willy)

  公开号：US20050277645A1

  公开（公告）日：2005-12-15

  Compounds having the following structure: including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R 1 , R 2a , R 2b , R 3 , R 4 , R 5a , R 5b , L 1 , L 2 and n are as defined herein. Pharmaceutical compositions containing one or more compounds of structure (I), as well as methods relating to the use thereof, including methods for treating insomnia, inducing sleep or inducing sedation or hypnosis, are also disclosed.

  以下具有以下结构的化合物，包括立体异构体，前药和其药物可接受的盐，其中R1，R2a，R2b，R3，R4，R5a，R5b，L1，L2和n的定义如下。还公开了含有结构（I）中一种或多种化合物的制药组合物，以及与其使用相关的方法，包括用于治疗失眠，诱导睡眠或诱导镇静或催眠的方法。
• Facile Benzylic Alkylation of Arenes with Alcohols by Catalysis with Spirocyclic NHC Ir ^III Pincer Complex
  作者：Kun‐Long Dai、Qi‐Long Chen、Wen‐Ping Xie、Ka Lu、Zhi‐Bo Yan、Meng Peng、Chang‐Kun Li、Yong‐Qiang Tu、Tong‐Mei Ding

  DOI：10.1002/anie.202206446

  日期：2022.9.19

  A facile IrIII-catalyzed benzylic alkylation of arenes with alcohols has been accomplished via borrowing hydrogen (BH) pathways, and the newly developed spirocyclic NHC IrIII pincer complex (Cat A) serves as an efficient catalyst for this atom-economical and greener transformation. Some drug or bioactive molecules and functional material templates can be easily constructed by this strategy.

  通过借氢 (BH) 途径实现了一种简单的 Ir III催化的芳烃与醇的苄基烷基化，新开发的螺环 NHC Ir III钳形配合物 (Cat A) 可作为这种原子经济和绿色转化的有效催化剂. 一些药物或生物活性分子和功能材料模板可以通过这种策略轻松构建。
• Characterization of Novel Selective H₁-Antihistamines for Clinical Evaluation in the Treatment of Insomnia
  作者：Wilna J. Moree、Bin-Feng Li、Florence Jovic、Timothy Coon、Jinghua Yu、Raymond S. Gross、Fabio Tucci、Dragan Marinkovic、Said Zamani-Kord、Siobhan Malany、Margaret J. Bradbury、Lisa M. Hernandez、Zhihong O’Brien、Jianyun Wen、Hua Wang、Samuel R. J. Hoare、Robert E. Petroski、Aida Sacaan、Ajay Madan、Paul D. Crowe、Graham Beaton

  DOI：10.1021/jm900933k

  日期：2009.9.10

  Analogues of the known H-1-antihistamine R-dimethindene were profiled as potential agents for the treatment of insomnia. Several highly selective compounds were efficacious in rodent sleep models. On the basis of overall profile, indene 1d and benzothiophene 2a had pharmacokinetic properties suitable for evaluation in night time dosing. Compound 2a did not show an in vivo cardiovascular effect from weak hERG channel inhibition.
• Structure−Activity Relationships of Dimethindene Derivatives as New M₂-Selective Muscarinic Receptor Antagonists
  作者：Thomas M. Böhme、Christine Keim、Kai Kreutzmann、Matthias Linder、Theo Dingermann、Gerd Dannhardt、Ernst Mutschler、Günter Lambrecht

  DOI：10.1021/jm020895l

  日期：2003.2.1

  A series of 2,3-disubstituted indenes, which are analogues of the widely used histamine H, receptor antagonist dimethindene, have been synthesized and studied as muscarinic and histamine receptor antagonists. The affinities of these compounds for the five human muscarinic receptor subtypes (M-1-M-5) and for human histamine H, receptors were determined in radioligand binding studies using membranes from transfected Chinese hamster ovary (CHO) cells and [H-3]N-methylscopolamine ([H-3]NMS). The results demonstrate that the diisopropyl analogue 19 has a similar high affinity as (S)-dimethindene at M-2 receptors ((S)-dimethindene: pK(i) = 7.52; (-)-19: pK(i) = 7.37) with an improved selectivity pattern ((S)-dimethindene: M-2/M-1 = 6-fold, M-2/M-3 = 5-fold, M-2/M-4 = 10-fold, M-2/M-5 = 25-fold; (-)-19: M-2/M-1 = 36-fold, M-2/M-3 = 96-fold, M-2/M-4 = 42-fold, M-2/M-5 = 275-fold). In addition, compound (-)-19 showed 35-fold lower affinity at histamine H-1 receptors (pK(i) = 5.61) than (S)-dimethindene (pK(i) = 7.16). Another interesting compound is the fluoroethyl derivative 20 (pK(i)/M-2 = 7.49), which also exhibits a higher M-2 selectivity (M-2/M-1 = 19-fold; M-2/M-3 = 22-fold; M-2/M-4 = 13-fold; M-2/ M-5 = 62-fold) than (S)-dimethindene. Unfortunately, compound 20 also shows a high affinity for histamine H-1 receptors (pK(i) = 8.14). The compound with the highest affinity for M-2 receptors (pK(i) = 7.91), the dimethylaminomethylene analogue 31, displayed only a small preference for M-2 receptors. In conclusion, compound (-)-19 might be useful to test the hypothesis that blockade of muscarinic M-2 receptors in the brain is a viable mechanism by which to produce improved cognition. This second-generation dimethindene analogue might also be the starting point for the development Of M-2-selective muscarinic antagonists useful for quantifying M-2 receptors in the central nervous system with positron emission tomography imaging.